What is the clinical effectiveness and cost effectiveness of PlGF-based tests to aid in the clinical diagnosis of pre-eclampsia in women presenting with suspected pre-eclampsia between 20 weeks and 36 weeks and 6 days of pregnancy?
Two placentally-derived biomarkers (sFlt-1 and PlGF) are detectable in the circulation of pregnant people. The levels of these markers are altered in pre-eclampsia. PlGF-based tests are intended to be used alongside current standard of care.
Diagnostics Guidance published by NICE in 2022 recommends four placental growth factor (PlGF)-based tests, intended for use alongside standard clinical assessment, to help decide on care for people with suspected preterm pre-eclampsia. The Scottish Health Technologies Group (SHTG) were asked to adapt the NICE guidance for NHSScotland, to inform a Scotland-specific approach to the use of PlGF testing.